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Background: Galectin-9 (Gal-9) induces apoptosis in activated T helper 1 (TH1) cells as a ligand for T cell
immunoglobulin mucin-3 (Tim-3). Gal-9 also inhibits the G1 phase cell cycle arrest and hypertrophy in db/db mice,
the hallmark of early diabetic nephropathy, by reversing the high glucose-induced up-regulation of cyclin
dependent kinase inhibitors such as p27Kip1 and p21Cip1.
Methods: We investigated the serum levels of Gal-9 in the patients with type 2 diabetes and various stages of
chronic kidney disease (CKD) (n=182).
Results: Serum Gal-9 levels in the patients with type 2 diabetes were 131.9 ± 105.4 pg/ml and Log10Gal-9 levels
significantly and positively correlated with age (r=0.227, p=0.002), creatinine (r=0.175, p=0.018), urea nitrogen
(r=0.162, p=0.028) and osmotic pressure (r=0.187, p=0.014) and negatively correlated with estimated glomerular
filtration rate (eGFR) (r=−0.188, p=0.011). Log10Gal-9 levels increased along with the progression of GFR categories
of G1 to G4, and they were statistically significant by Jonckheere-Terpstra test (p=0.012). Log10Gal-9 levels remained
similar levels in albuminuria stages of A1 to A3.
Conclusion: The elevation of serum Gal-9 in the patients with type 2 diabetes is closely linked to GFR and they
may be related to the alteration of the immune response and inflammation of the patients with type 2 diabetes
and CKD.
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Galectins are β-galactoside binding protein and involved in
various biological processes such as development, organo-
genesis, oncogenesis, cell adhesion, cell cycle regulation
and immunity [1]. Mouse and rat galectin-9 (Gal-9) was
identified [2,3] and its human homologue was independ-
ently cloned by using autoreactive antibodies in Hodgikin’s
disease [4]. Galectin-9 exerted apoptotic potential against
thymocytes [2], suggesting their important roles in the
negative selection of thymocytes. Gal-9 lacking signal pep-
tide is secreted out by non-classical pathway under* Correspondence: junwada@md.okayama-u.ac.jp
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reproduction in any medium, provided the orinflammatory state and induced apoptosis in activated
CD8+ T cells [5,6] and activated T helper 1 (TH1) cells [7],
suggesting a potential mechanism to eliminate the acti-
vated T cells at termination of the immune response in
inflammatory tissues. T cell immunoglobulin mucin-3
(Tim-3) has been identified as a receptor for Gal-9, Gal-9
induces apoptosis in CD4+Tim-3+ TH1 cells, and Gal-9-
Tim-3 pathway negatively regulates TH1 immunity [7].
In addition to apoptotic potential to immune mediated
cells, Gal-9 is a cell cycle regulator and it altered the status of
cell proliferation and cell cycle arrest. In diabetic nephropa-
thy, G1 phase cell cycle arrest and hypertrophy in mesangial
and glomerular epithelial cells are the characteristic patho-
logical change and up-regulation of cyclin dependent kinase
inhibitors such as p27Kip1 and p21Cip1 are critically involvedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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9 into db/db mice inhibited the glomerular hypertrophy and
albuminuria, and Gal-9 reversed up-regulation of p27Kip1
and p21Cip1 and promoted the progression of cell cycle from
G1 phase in cultured mesangial cells [8].
The line of evidences led us to investigate the serum
levels of Gal-9 in the patients with type 2 diabetes and
various stages of chronic kidney disease (CKD), since the
alteration of serum Gal-9 levels may influence the status
of immune responses and cell cycle regulation in the
various cells including kidney cells.
Methods
Patients
Japanese patients with type 2 diabetes (n=182, 60.4 ± 14.4
years) were enrolled into this study. The patients with type 2
diabetes were treated with oral hypoglycemic agents
(n=132), insulin treatment (n=72) or both (n=32). The
patients with eGFR < 15 ml/min/1.73 m2 or under dialysis
were excluded from the current study. All recruited patients
with type 2 diabetes agreed to measure serum Gal-9 levels.
The study was conducted in accordance with the ethical
principle of the Declaration of Helsinki and approved by
ethical committee of Okayama University Graduate School
of Medicine, Dentistry and Pharmaceutical Sciences. We
obtained informed consent from each patient.
Blood sampling and assays
We measured overnight fasting serum levels of total chol-
esterol and low density lipoprotein (LDL) cholesterol, high
density lipoprotein (HDL) cholesterol, triglycerides (L Type
Wako Triglyceride · H, Wako Chemical, Osaka), uric acid,
serum creatinine (Cr), serum urea nitrogen (UN), plasma
glucose, and HbA1c. Urinary albumin was measured in
random spot urine samples by standard immuno-
nephelometric assay. The urinary albumin-creatinine ratio
(ACR) was calculated. Estimated glomerular filtration rate
(eGFR) was calculated by equation; eGFR (ml/min/1.73
m2)=194 × Cr-1.094 × age-0.287 in male and eGFR (ml/min/
1.73 m2)=194 × Cr-1.094 × age-0.287 × 0.739 in female [9]. By
using the definition and classification of chronic kidney
disease [Kidney Disease: Improving Global Outcomes
(KDIGO)] [10], all patients were classified into albuminuria
and GFR category. In albuminuria stages, the patients were
classified into three groups; A1 (<30 mg/gCr), A2 (30–299
mg/gCr) and A3 (≥300 mg/gCr). In GFR stages, they were
classified into 4 groups; G1 (≥90 ml/min/1.73 m2), G2
(60–89 ml/min/1.73 m2), G3 (30–59 ml/min/1.73 m2), and
G4 (15–29 ml/min/1.73 m2). Osmotic pressure was calcu-
lated by osmotic pressure (mOSM/l)=2×[Na (mmol/l) +K
(mmol/l)]+[plasma glucose (mg/dl) / 18)+[UN (mg/dl) /
2.8]. Serum Gal-9 levels were measured with ELISA kit for
human Gal-9 (Uscn, Wuhan, P.R. China). According to the
manufacturer’s data sheet, sensitivity is less than 2.8 pg/mland no significant cross-reactivity or interference among
human Gal-9 and analogues was observed.
Statistical analysis
All data are expressed as mean ± standard deviation (SD)
values. Since serum Gal-9 concentrations did not show
normal distribution, they were log-transformed and non-
parametric tests were employed. Spearman correlation
coefficients were used to evaluate whether serum Log10-
Gal-9 levels correlated with various parameters. To deter-
mine the variables independently associated with serum
Gal-9 levels in the patients with type 2 diabetes, multiple
regression analysis was performed by including age, os-
motic pressure and eGFR as independent variables. Gal-9
levels and various clinical parameters in albuminuria and
GFR stages were compared by Jonchheere-Terpstra test.
Jonchheere-Terpstra test is similar to Kruskal-Wallis test
but applied to samples with a priori ordering, e.g., stages
of disease. P values less than 0.05 were considered statisti-
cally significant. Statistical analysis was performed with
PASW Statistics 18 (SPSS Inc., Chicago, IL).
Results
Serum Gal-9 levels correlated with age, Cr, UN, eGFR and
osmotic pressure
Serum Gal-9 did not show correlation with blood glucose,
HbA1c levels and variation of the treatments in type 2 dia-
betes. Serum Gal-9 levels in the patients with type 2 diabetes
were 131.9 ± 105.4 pg/ml. Serum Gal-9 levels significantly and
positively correlated with age (r=0.227, p=0.002), Cr (r=0.175,
p=0.018), UN (r=0.162, p=0.028) and osmotic pressure
(r=0.187, p=0.014) (Figure 1A-1C, 1E). Serum Gal-9 levels sig-
nificantly and negatively correlated with eGFR (r=−0.188,
p=0.011) (Figure 1D). The linear regression analyses were fol-
lowed by a stepwise multiple regression analysis using serum
Gal-9 levels as the dependent variables to further analyze the
significant predictors (Table 1). Age, osmotic pressure and
eGFR were used as independent variables. By stepwise analysis
in model 1, only osmotic pressure independently correlated
with serum Gal-9 levels. By including all variables demonstrat-
ing significant simple correlation with serum Gal-9 levels, only
osmotic pressure significantly predicted the serum Gal-9 levels
but other parameters did not enter the equation at significant
levels in model 2 (Table 1).
Serum Gal-9 levels elevated with the progression of GFR
stages
Next, we investigated the serum Gal-9 levels in various
stages of CKD. Age, ACR, Cr, UN, eGFR and osmotic
pressure were significantly increased during the progres-
sion of GFR stages by Jonckheere-Terpastra test (Table 2).
Log10Gal-9 levels also increased in the later stages of GFR
and they were statistically significant by Jonchheere-
Terpstra test (p=0.012) (Table 2 and Figure 1F). Since age
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Figure 1 Serum galectin-9 levels in the patients with type 2 diabetes (n=182). The simple correlations of Log10Gal-9 and various
parameters; age (A), serum creatinine (B), serum urea nitrogen (C), estimated glomerular filtration rate (eGFR) (D), and osmotic pressure (E).
Log10Gal-9 levels are also shown in GFR stages and albuminuria stages and differences are analyzed by Jonckheere-Terpstra test (F).
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we selected the patients older than 60 years old (n=107)
and performed Jonckheere-Terpastra analysis. Log10Gal-9
levels were still statistically different in G1 to G4 stages
(p = 0.046). In albuminuria stages, ACR, Cr, UN, eGFR
and osmotic pressure were significantly altered by Jonckheere-
Terpstra (Table 3). However, Log10Gal-9 levels remained simi-
lar levels in A1 to A3 stages (Table 3 and Figure 1F).Discussion
The presence of galectin-9 in human serum was well-
documented in previous reports. Serum galectin-9 was ele-
vated in hepatitis C infection and it was released from
Kupffer cells in the liver [11]. In addition, oral administra-
tions of dietary synbiotic bacteria such as Bifidobacterium
breve M-16V increased the expression of galectin-9 in in-
testinal epithelial cells, increased serum galectin-9 levels,
Table 1 Multiple linear regression analysis in the patients with type 2 diabetes (n=182) using serum galectin-9 levels
as dependent variables
Model Independent variables Unstandardized coefficient Standardized coefficients t
value
P
value
Model
r2B Standard Error Beta
1 Osmotic pressure (mmol/kg) 0.020 0.006 0.239 3.187 0.002 0.057
2 Age (year) 0.003 0.003 0.102 1.141 0.255 0.068
Osmotic pressure (mmol/kg) 0.018 0.007 0.209 2.521 0.013
eGFR (mL/s) −0.012 0.102 −0.011 −0.113 0.910
Age, osmotic pressure and estimated glomerular filtration rate (eGFR) are used as independent variables in stepwise multiple linear regression analysis in model 1.
In model 2, all parameters are included in the analysis.
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is also stimulated and released from various cells by
interferon-γ in human endothelial cells [13], fibroblasts
[14], pancreatic β cells [15], and Kupffer cells [11].
Galectin-9 is vulnerable to digestion by proteolytic degrad-
ation; however, it was reported that galectin-9 is inserted
into exosome and released, thus it is protected by enzym-
atic degradation, and the intact 36 kDa molecule was
demonstrated in the serum exosome fraction [16].
Galectin-9 is also abundantly expressed in the cytoplasm of
tubular cells and kidney may contribute the circulating
Gal-9; however, regulation of the release of Gal-9 from kid-
ney cells is completely unknown [2,3].
In current clinical investigation, simple correlation of
Log10Gal-9 levels with age, Cr, UN, and eGFR suggestedTable 2 Comparison of various parameters in glomerular filtr
patients (n=182)
G1 G2 G3
Number (male/female) 37 (21 / 16) 99 (37 / 62) 41 (12
Age (years) 50.0±15.5 60.7±10.8 70.2±
BMI (kg/m2) 27.0±6.9 25.5±4.8 24.7±
SBP (mmHg) 128.9±14.7 129.7±15.4 129.6
DBP (mmHg) 77.7±10.8 74.5±10.9 73.1±
PG (mmol/L) 9.6±4.2 8.6±3.1 8.8±3
HbA1c (%) 7.90±1.54 7.25±1.01 7.13±
HbA1c (mmol/mol) 65.3±16.0 58.5±10.5 57.3±
ACR (mg/gCr) 19.6±27.7 130.6±344.4 421.4
Cr (μmol/L) 49.5±8.8 66.3±11.5 94.6±
UN (mmol/L) 4.7±1.6 5.7±1.6 20.6±
eGFR (mL/s) 1.76±0.26 1.25±0.14 0.85±
Osmotic pressure (mmol/kg) 299.3±4.0 301.2±4.3 303.0
T-Cho (mmol/L) 4.77±0.81 4.93±0.88 4.80±
TG (mmol/L) 1.51±0.74 1.51±0.77 1.68±
HDL-C (mmol/L) 1.48±0.36 1.61±0.54 1.53±
LDL-C (mmol/L) 2.67±0.70 2.79±0.68 2.73±
Log10Gal-9 (pg/mL) 1.89±0.41 1.94±0.42 2.02±
BMI, body mass index; SBP, Systolic Blood Pressure; DPB, Diastolic Blood Pressure; P
serum urea nitrogen; eGFR, estimated glomerular filtration ratio; T-Cho, Total choles
Log10Gal-9, Log10galectin-9 (pg/mL). *, p < 0.05; **, p < 0.01.that serum Gal-9 levels closely related to the renal function
in patients with type 2 diabetes. The molecular weight of
Gal-9 is ~36 kDa and it would be filtered through glom-
erular capillaries and the reduction of GFR may be linked
to the elevation of serum Gal-9 levels. Actually, log10Gal-9
levels increased along with the progression of GFR stages,
i.e. G1 to G4. In diabetic kidney disease, albuminuria also
increased during the progression of the disease and Gal-9
may be actively filtered through glomerular basement
membranes; however, serum Gal-9 levels did not negatively
correlate with urinary albumin excretion and serum Gal-9
levels were not altered in the progression of albuminuria
stages from A1 to A3. Although both of the reduced filtra-
tion of Gal-9 and loss of Gal-9 into the urine may be the
determinants for the serum Gal-9 levels, the currentation stages of chronic kidney disease in type 2 diabetes
G4 Total Jonckheere-Terpstra
/ 29) 5 (1 / 4) 182 (71 / 111) 0.009**
11.7 73.8±7.8 60.4±14.4 6.43×10-10**
4.0 25.9±1.7 25.6±5.1 0.242
±18.3 128.2±18.4 129.5±15.9 0.939
12.9 67.4±9.8 74.7±11.4 0.031*
.1 8.6±3.1 8.9±3.3 0.113
0.78 7.04±0.88 7.35±1.12 0.029*
8.1 73.1±9.1 76.4±11.6 0.029*
±1191 702.1±603.0 196.6±655.0 0.005**
23.0 245.8±114.9 74.3±39.8 3.45×10-21**
7.4 15.7±2.1 6.1±2.5 1.60×10-9**
0.13 0.33±0.10 1.24±0.37 8.80×10-30**
±4.2 312.9±1.2 301.6±4.8 4.78×10-6**
1.30 5.05±0.90 4.87±0.97 0.736
0.91 2.19±1.16 1.56±0.81 0.391
0.45 1.27±0.06 1.56±0.49 0.776
0.80 3.09±0.99 2.75±0.72 0.753
0.43 2.27±0.32 1.96±0.42 0.012*
G, Plasma glucose; ACR, albumin / creatinine ratio; Cr, serum creatinine; UN,
terol; TG, Triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol;
Table 3 Comparison of various parameters in albuminuria stages of chronic kidney disease in type 2 diabetes patients
(n=182)
A1 A2 A3 Total Jonckheere-Terpstra
Number (male/female) 108 (46 / 62) 47 (17 / 30) 27 (8 / 19) 182 (71 / 111) 0.075
Age (years) 60.0±14.0 63.5±13.5 62.0±12.7 60.4±14.4 0.199
BMI (kg/m2) 25.3±1.5 26.2±6.2 27.3±5.1 25.6±5.1 0.227
SBP (mmHg) 128.8±13.3 132.7±19.7 137.0±20.0 129.5±15.9 0.071
DBP (mmHg) 75.1±9.9 72.7±13.1 78.3±16.6 74.7±11.4 0.982
PG (mmol/L) 8.5±3.0 9.6±3.9 9.1±2.7 8.9±3.3 0.170
HbA1c (%) 7.27±0.87 7.51±1.35 7.61±1.41 7.35±1.12 0.611
HbA1c (mmol/mol) 75.5±9.0 78.0±14.0 79.0±14.6 76.3±11.6 0.611
ACR (mg/gCr) 11.2±6.2 110.7±83.4 1474±1444 196.6±655.0 5.06×10-23**
Cr (μmol/L) 69.0±40.7 73.4±19.4 114.9±53.9 74.3±39.8 2.44×10-4**
UN (mmol/L) 5.8±2.1 6.5±1.9 9.1±4.1 6.1±2.5 2.04×10-4**
eGFR (mL/s) 1.29±0.34 1.17±0.30 0.86±0.37 1.24±0.37 2.55×10-4**
Osmotic pressure (mmol/kg) 301.0±4.0 300.9±4.7 306.7±4.8 301.6±4.8 0.013*
T-Cho (mmol/L) 4.85±0.92 5.00±1.17 4.98±0.94 4.87±0.97 0.688
TG (mmol/L) 1.44±0.71 1.75±0.82 1.72±0.84 1.56±0.81 0.051
HDL-C (mmol/L) 1.57±0.49 1.52±0.51 1.56±0.54 1.56±0.49 0.413
LDL-C (mmol/L) 2.77±0.62 2.90±0.85 2.78±0.77 2.75±0.72 0.890
Log10Gal-9 (pg/mL) 1.97±0.43 1.90±0.45 1.98±0.30 1.96±0.42 0.374
BMI, body mass index; SBP, Systolic Blood Pressure; DPB, Diastolic Blood Pressure; PG, Plasma glucose; ACR, albumin / creatinine ratio; Cr, serum creatinine; UN,
serum urea nitrogen; eGFR, estimated glomerular filtration ratio; T-Cho, Total cholesterol; TG, Triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol;
Log10Gal-9, Log10galectin-9 (pg/mL). *, p < 0.05; **, p < 0.01.
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Gal-9 levels.
In addition to GFR, serum Gal-9 levels also revealed
simple correlation with osmotic pressure. Since serum
osmotic pressure is determined by the concentrations of
sodium, potassium, plasma glucose and UN, the osmotic
pressure in the patients of type 2 diabetes would be ele-
vated by the impairment of renal function or by hyper-
glycemia. Multiple linear regression analysis revealed
that osmotic pressure is only significant predictor for
serum Gal-9 levels by employing age, osmotic pressure
and eGFR as independent variables. A novel model for
non-classical secretion of fibroblast growth factor 1
(FGF1), FGF2, and galectins without signal peptide have
been reported, namely oncotic release, where a change
in the colloidal osmotic pressure by serum deprivation
in the culture cells creates the nonlethal oncotic pores in
the plasma membranes through which proteins are
released [17]. There are no reports whether the increase
in osmotic pressure alters the plasma membrane and it
stimulates the secretion of Gal-9 via non-classical path-
way; however, the current study suggested that osmotic
pressure might be the stimulator for the release of Gal-9
and the future studies are required to support this
evidence.
Since the current investigation is cross-sectional clinical
study, it is difficult to conclude whether elevated serumGal-9 levels are protective or promoting for the progres-
sion of diabetic nephropathy. Gal-9 induces apoptosis in
CD4+Tim-3+ TH1 cells, and Gal-9-Tim-3 pathway nega-
tively regulates TH1 immunity, thus the elevation of serum
Gal-9 may be beneficial in the progression of diabetic
nephropathy by negatively regulating the immune
responses and inflammation [18]. In addition, the eleva-
tion of serum Gal-9 concentrations may inhibit the G1
cell cycle arrest and hypertrophy of the kidney cells [8].
Thus, the follow-up cohort study may be required to clar-
ify whether the elevated serum Gal-9 levels in type 2 dia-
betes are preventive for the progression of diabetic
nephropathy. In recent series of the investigations, Gal-9
is also reported to regulate the virus specific T-cell re-
sponse [19], T cell immunity in hepatitis C infection [11],
anti-microbial immunity [20], it is an important clinical
question whether elevated serum levels of Gal-9 in the
patients with type 2 diabetes and diabetic nephropathy are
related to the susceptibility for various infection in the fu-
ture studies.
Conclusion
Serum Gal-9 levels in the patients with type 2 diabetes
significantly and positively correlated with age, creatin-
ine, urea nitrogen and osmotic pressure and negatively
correlated with estimated glomerular filtration rate
(eGFR). Log10Gal-9 levels increased along with the
Kurose et al. BMC Nephrology 2013, 14:23 Page 6 of 6
http://www.biomedcentral.com/1471-2369/14/23progression of GFR categories of G1 to G4, and they
were statistically significant by Jonckheere-Terpstra test
(p=0.012). The elevation of serum Gal-9 in the patients
with type 2 diabetes is closely linked to GFR and they
may be related to the alteration of the immune response
and inflammation of the patients with type 2 diabetes
and CKD.
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